Copy of Approach

Advances in the genetics and cell biology underlying CNS Disorders have identified pathways that contribute to disease onset and progression. We plan to apply deep scientific and drug development expertise to harvest the full potential of these advances to develop safe and effective therapeutics.

drug development Pipeline

While psychedelics are emerging as an important component of the mental healthcare revolution, we are still in the early days. It is important to recognize that providing a comprehensive response to the global mental health crisis is key. This comprehensive response leverages insights from CNS research (including research in psychedelics), as well as enhancements in drug discovery and development, including brain imaging and genomics. To this end, we are repurposing medicines using powerful and proven approaches.

Development Strategy

Rather than focus on a single product or indication, the larger opportunity lies in building a robust and diverse product pipeline of high-value potential drug candidates to treat psychiatric illnesses.

Partnering is a key part of our strategy and our team of drug hunters is continuously on the lookout for innovative technologies and assets with strong patents. We take a broad, multi-pronged approach to identify drugs that can be repurposed as drug candidates for psychiatric disorders. Additionally, our approach combines natural products chemistry with medicinal chemistry to improve therapeutic properties.

Our pipeline development strategy reflects a blended approach to manage risk and catalyze partnerships that enable access to non-dilutive capital, and increase speed.

Team History - Drug Repurposing

Drug repurposing refers to the process of identifying new indications for existing FDA-approved drugs, product candidates under development, and abandoned compounds. Our team has successfully worked together to repurpose drugs in several other successful companies like these and has created significant value for patients and stakeholders.

Plants With CNS Active Compounds

We take what is known but understudied from ethnobotanists and make judicious selections of botanical/fungal candidates from global bioresources. These candidates, with known CNS activities, have been used in cultural and traditional medicine for centuries.

The psychoactive agents of these plants are isolated and characterized, both chemically and pharmacologically, and used as leads in our drug discovery programs. In contrast to traditional drug discovery programs of pharma and biotech, we plan to test the natural products in human subjects, before investing to develop NCE's that have superior characteristics.

After performing the requisite safety and efficacy studies, we may out-license patented plant extracts to others to market as nutraceuticals rather than directly selling plant extracts ourselves.